CompletedPhase 2ACTRN12605000756628

Continued use of Atorvostatin in sepsis

A phase II randomised controlled trial in patients on statin therapy who develop sepsis to evaluate the effect of continued atorvastatin use on the incidence of severe sepsis

Sponsor

Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane

Enrollment

200 participants

Start Date

May 8, 2006

Study Type

Interventional

Conditions

Sepsis / infection in patients taking statin therapy

Summary

study completed and the results are now published in the American journal of Respiratory and critical care medicine

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Continued use of Atorvostatin in sepsis. It is looking for adults aged 18 and older who may be eligible to participate. Participants may need to meet certain health requirements, including: all patients with sepsis syndrome who are on statin therapy at the time of admisison to hospital are eligable for inclusion. Some medical conditions may prevent you from joining this study.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Atorvostatin as continuation of statin therapy for a 28 day study period ( or until discharge form hospital)

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000756628